Gufic Pharma Limited, a amalgamated public limited company, was established on 25 June 1983 in Ahmedabad, Gujarat, India. Engaging in pharmaceutical retailers & distributors within the pharma sector, it holds CIN: U24231GJ1983PLC006323. Registered under ROC Roc Ahmedabad. it is unlisted. It has an authorized capital of ₹0.50 M and a paid-up capital of ₹0.50 M.
Its leadership includes Prince Kalarickal Elias (Director), Sanjay Jerry (Director), Sandeep Mehandroo (Director). Past directors included Udai Upendra, Sanjeev Indravadan Dani, Meetal Sharad Sampat. It holds no open charges and ₹1.36 Cr settled loans. Its latest AGM occurred on 07 August 2017, with the balance sheet filed on 31 March 2017. It is based at G-7-8-9 Metro Commeri Cal Centre Ashram Road, Ahmedabad, Gujarat, 380009.
U24231GJ1983PLC006323
006323
25 June 1983
₹0.50 M
₹0.50 M
Roc Ahmedabad
Unlisted
Amalgamated
Explore comprehensive insights into Gufic Pharma Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Prince Kalarickal Elias | Director | 15 Feb 2016 | Current |
| Sanjay Jerry | Director | 07 Mar 2014 | Current |
| Sandeep Mehandroo | Director | 30 Nov 2012 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 05 Jun 2009 | Past |
| Pramod Abcsdd | Director | 07 Mar 2014 | Past |
| Pramod Abcsdd | Director | 15 Feb 2016 | Past |
| Pramod Abcsdd | Additional Director | 28 Sep 2016 | Past |
| Pramod Abcsdd | Additional Director | 31 Aug 2015 | Past |
| Pramod Abcsdd | Additional Director | 24 Nov 2014 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Gufic Pharma Limited, for the financial year ended 2016, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
In 2017, Gufic Pharma had a promoter holding of 98.00% and a public holding of 2.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹13,625,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Feb 1992 | The Saraswat Co-Operative Bank Ltd | ₹3.50 M | Satisfied |
| 06 Feb 1990 | Bharat Overseas Bank Ltd | ₹2.50 M | Satisfied |
| 11 Jan 1990 | Canara Bank | ₹0.50 M | Satisfied |
| 19 Oct 1985 | Canara Bank | ₹1.00 M | Satisfied |
| 24 Jul 1984 | Canara Bank | ₹1.40 M | Satisfied |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Gufic Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Gufic Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gufic Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Gufic Pharma Limited last Annual general meeting of members was held on 07 Aug 2017 as per latest MCA records. was documented.
The activity Gufic Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2017 with Roc Ahmedabad. was completed.
The activity A charge registered on 11 Jan 1990 via Charge ID 90097385 with Canara Bank was fully satisfied on 28 Jun 2016. was completed.
The activity A charge registered on 19 Oct 1985 via Charge ID 90097170 with Canara Bank was fully satisfied on 28 Jun 2016. was completed.
The activity A charge registered on 24 Jul 1984 via Charge ID 90097141 with Canara Bank was fully satisfied on 28 Jun 2016. was completed.
A charge registered on 24 Jul 1984 via Charge ID 90100172 with Canara Bank was fully satisfied on 28 Jun 2016. was recorded as a recent event.
Sun Pharmaceutical Industries plans to acquire all outstanding shares of Taro Pharmaceutical Industries for $43 per share in cash, aiming to gain complete control over its subsidiary.
Sun Pharma has partnered up with Bayer to market Finerenone, a drug for chronic kidney disease, in India. Bayer grants non-exclusive rights to Sun Pharma to distribute Finerenone under the brand name Lyvelsa. Sun Pharma CEO emphasizes commitment to providing innovative medicines to Indian patients. .
The CIN of Gufic Pharma Limited is U24231GJ1983PLC006323.
Gufic Pharma Limited is headquartered at G-7-8-9 Metro Commeri Cal Centre Ashram Road, Ahmedabad, Gujarat, 380009.
Gufic Pharma Limited was incorporated on 25 June 1983.
The current directors of Gufic Pharma Limited are
The primary industry of Gufic Pharma Limited is Pharma.
Gufic Pharma Limited is unlisted.
The authorized capital of Gufic Pharma Limited is ₹0.50 M, and the paid-up capital is ₹0.50 M.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX